PetVivo Holdings (OTCQB: PETV) has announced that it will discontinue separate quarterly earnings press releases and scheduled earnings conference calls, consolidating its financial reporting into mandatory SEC filings. The change begins with the company’s second-quarter fiscal 2027 report, scheduled for filing on 13 November 2026.
PetVivo Holdings Inc., a biomedical device company focused on medical devices and therapeutics for companion animals and horses, has announced a change in its quarterly investor-communications strategy.
In a statement released on 11 November 2026, the company said that beginning with its quarterly report for the fiscal second quarter ended 30 September 2026, it does not intend to issue separate quarterly financial-results press releases or conduct quarterly earnings conference calls.
Instead, the company will communicate its quarterly financial results and related disclosures through filings with the US Securities and Exchange Commission (SEC).
PetVivo said it planned to file its Form 10-Q on 13 November 2026.
The company stated that its financial information will remain publicly accessible through the SEC’s EDGAR database and that shareholders will continue to be able to contact management with questions and requests for discussion.
A change in reporting format, not an end to regulatory disclosure
The announcement represents a change in the format of investor communications rather than a decision to stop reporting financial performance. As an OTCQB-listed company, PetVivo remains subject to applicable reporting obligations.
The Form 10-Q will continue to provide the company’s required quarterly financial information and related disclosures. The SEC filing system provides investors with access to financial statements, management discussion, risk factors and other information required under applicable securities regulations.
The company has encouraged shareholders to review its filings through EDGAR. PetVivo has also indicated that it may revisit its approach as its business and investor base evolve.
Why the decision is relevant for investors
Separate earnings announcements and conference calls are commonly used by listed companies to explain financial performance, discuss operating trends and answer investor questions.
By relying primarily on regulatory filings, companies can consolidate disclosures into a single formal reporting channel. However, the change may affect how investors receive and interpret quarterly information.
A conventional earnings release often provides a concise summary of revenue, expenses, cash position, operating milestones and management commentary. An earnings call also allows investors and analysts to ask questions about financial performance, product adoption, commercial strategy and future expectations.
When these separate formats are discontinued, investors may need to rely more heavily on the regulatory filing and direct communication with management.
PetVivo’s animal-health business
PetVivo describes itself as a biomedical device company focused on the development, manufacturing, commercialisation and licensing of medical devices, biomaterials and therapeutics for animal and human health.
Its portfolio includes products intended for the management of joint-related conditions in animals. The company’s lead product, SPRYNG with OsteoCushion technology, is a veterinarian-administered intra-articular injection marketed for the management of lameness and joint-related afflictions, including osteoarthritis, in dogs, cats and horses.
The company also reports a portfolio of issued and pending patents and trade secrets protecting its technologies, products and manufacturing processes.
Its commercial performance is therefore relevant to the broader veterinary medical-device market, particularly the development and adoption of biomaterial-based products for musculoskeletal conditions.
What investors should examine in the September-quarter Form 10-Q
The filing due on 13 November will be important for assessing the company’s financial and commercial position. Investors may wish to examine the following areas:
1. Revenue performance: Quarterly revenue and year-on-year growth will help indicate the pace of commercial adoption.
2. Gross margins: Manufacturing economics and product mix can influence the sustainability of commercial expansion.
3. Operating expenses: Research and development, sales, marketing and administrative costs will provide insight into the company’s cost structure.
4. Cash position: Cash, short-term liquidity and operating cash flow will be important for assessing financing requirements.
5. Commercial traction: Product distribution, veterinary-clinic adoption and repeat demand will be relevant to evaluating market penetration.
6. Product development: Progress in the pipeline and any new regulatory or commercial milestones could influence future growth.
7. Financing and dilution: Investors should review outstanding securities, potential financing arrangements and capital requirements.
These are areas for review, not claims about the contents of the forthcoming filing.
The potential implications of discontinuing earnings calls
The decision may reduce the frequency of structured management interaction with investors. For smaller public companies, conference calls can be an important channel for communicating strategic priorities, commercial milestones and operating challenges.
PetVivo has stated that it welcomes shareholder questions, feedback and requests for discussion following review of its reports.
This provides an alternative channel, although direct discussions are not necessarily equivalent to a scheduled public earnings call. The company has also said it anticipates potentially resuming quarterly earnings releases and conference calls in connection with a future uplisting to a national securities exchange.
Any such uplisting would remain subject to applicable listing requirements and approvals.
Outlook
PetVivo’s new reporting approach will place greater emphasis on SEC filings as the primary source of quarterly financial information.
The forthcoming September-quarter Form 10-Q will be the first important reporting document under the revised approach. Investors will need to assess the filing for revenue growth, liquidity, commercial progress and funding requirements.
For the animal-health industry, the announcement is primarily a corporate-governance and investor-relations development. It does not, by itself, indicate a change in PetVivo’s product portfolio, commercial strategy or regulatory status.
